Beta Finch - S&P 100 - EN

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.

JORDAN: And I'm Jordan. Today we're diving into Boston Scientific's fourth quarter and full year 2025 results - and wow, what a year it's been for this medical device giant.

ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Absolutely. So Alex, Boston Scientific just wrapped up what CEO Mike Mahoney called an "outstanding" year. Let's start with the headline numbers - they're pretty impressive.

ALEX: They really are. For the full year, Boston Scientific hit over $20 billion in sales - that's 19% operational growth and nearly 16% organic growth. They actually exceeded their guidance of around 15.5%. And on the bottom line? Adjusted earnings per share of $3.06, up 22% year-over-year.

JORDAN: That's their third consecutive year of 20%+ EPS growth, which is remarkable consistency in this industry. But what I found interesting was the fourth quarter specifically - 13% organic growth, which hit the high end of their guidance range. The question is, what's driving all this growth?

ALEX: Two words: EP and WATCHMAN. Their electrophysiology business grew 35% in Q4 and a staggering 73% for the full year. That's largely driven by their FARAPULSE technology - basically a next-generation treatment for atrial fibrillation that uses pulsed field ablation instead of traditional methods.

JORDAN: And WATCHMAN, their left atrial appendage closure device, grew 29% in the quarter. Mike Mahoney mentioned they've now treated more than 25,000 patients with what they call "concomitant procedures" - essentially doing WATCHMAN and EP procedures together, which is more efficient for hospitals.

ALEX: But here's where it gets really interesting - and where some investors got a bit nervous during the earnings call. There were questions about whether growth is slowing, especially in the U.S. EP market. Some analysts were expecting even higher numbers.

JORDAN: Right, and Mahoney pushed back on this pretty hard. He said competitors are claiming the EP market grew 25% in Q4, but Boston Scientific thinks it was more like 18-20%. And even at that growth rate, they're significantly outpacing competitors - some major players only grew 6.5% and 12.5% respectively.

ALEX: That's a crucial point for investors. Market share dynamics are shifting as competitors launch their own PFA products, but Boston Scientific believes they'll maintain clear market leadership. Mahoney said by year-end 2026, their PFA share might equal all other competitors combined, but they'll still be the leader.

JORDAN: And looking ahead, they're guiding for some pretty solid numbers in 2026. Organic revenue growth of 10-11% for the full year, though Q1 will be softer at 8.5-10% due to some one-time headwinds and tough comparisons.

ALEX: Those headwinds include discontinuing a product called ACURATE and a temporary withdrawal of certain sizes of their AXIOS device due to manufacturing issues. But they expect both situations to resolve by mid-year.

JORDAN: Let's talk about what could be a game-changer - the CHAMPION trial results. This is a major clinical study comparing their WATCHMAN device to blood thinners for stroke prevention. Dr. Ken Stein, their Chief Medical Officer, said results will be presented at the American College of Cardiology conference.

ALEX: If positive, this could be huge. Currently, WATCHMAN is indicated for about 5 million patients globally who can't tolerate blood thinners. But if CHAMPION shows WATCHMAN is as effective as blood thinners with better bleeding outcomes, that addressable market could jump to 20 million patients.

JORDAN: That would essentially position WATCHMAN as a first-line therapy instead of just for patients who ca

This episode includes AI-generated content.

# Beta Finch Podcast Script - Applied Materials Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into conversations you can actually follow. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Applied Materials' Q1 2026 earnings call - that's AMAT for those keeping score at home.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. So Applied Materials - for folks who might not know - they're basically the behind-the-scenes heroes making the tools that manufacture semiconductors. Think of them as the company that makes the machines that make the chips.

**ALEX:** Exactly. And what's interesting about this quarter is we're seeing some really strong AI-driven demand flowing through to their business. CEO Gary Dickerson opened by highlighting "strong demand across AI, foundry-logic, and memory" with customers accelerating their technology roadmaps.

**JORDAN:** Right, and that's showing up in their financials. While they didn't give us specific revenue numbers in this transcript, CFO Brice Hill mentioned they delivered "strong revenue, margins, and cash flow" and that their backlog remains elevated with book-to-bill around unity.

**ALEX:** That book-to-bill metric is key for equipment companies like Applied Materials. When it's at or above 1.0, it means they're booking new orders at the same rate or faster than they're shipping products. It's a good leading indicator of future revenue.

**JORDAN:** What really caught my attention was the breadth of growth drivers they're seeing. It's not just one area - they mentioned AI, advanced packaging, HBM memory, and even improvements in both DRAM and NAND flash memory.

**ALEX:** HBM is High Bandwidth Memory, by the way - it's the super-fast memory that AI chips need to process all that data. Gary Dickerson specifically called out "strong pull for tools supporting HBM" with visibility extending through multiple quarters.

**JORDAN:** And here's something I found fascinating - they're not just riding the AI wave passively. When asked about advanced packaging, Dickerson talked about their "comprehensive toolset across wafer-level packaging, hybrid bonding, and inspection/metrology." They're positioning themselves across the entire value chain.

**ALEX:** That's Applied Materials' sweet spot - materials engineering. They keep emphasizing these complex new chip architectures like gate-all-around transistors and backside power delivery, which create "new materials and integration challenges" where their expertise becomes even more valuable.

**JORDAN:** Speaking of challenges, there was an interesting exchange about China and export controls. Dickerson said demand there "remains mixed by segment, with mature nodes steady and certain leading-edge areas impacted by restrictions." But they seem to be managing this well with their global footprint.

**ALEX:** Right, and what I appreciated was their transparency about supply chain issues. Brice Hill mentioned they're "expanding capacity in critical product lines" and that lead times are improving as they qualify additional suppliers. That's exactly what you want to hear from a company in this space.

**JORDAN:** The services business also looks solid. Hill talked about growth being "supported by our expanding installed base" and higher attachment to performance-based agreements. That's recurring revenue, which investors love because it's more predictable than equipment sales.

**ALEX:** Let's talk about what this means looking forward. One analyst asked about sustainability of AI demand, and Dickerson seemed pretty confident, saying their "pipeline and customer engagements give us conf

This episode includes AI-generated content.

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode quarterly reports so you don't have to. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Bristol Myers Squibb's Q4 2025 earnings call - and let me tell you, this one was packed with updates.

But first, Jordan, I need to get our mandatory disclaimer out of the way. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And speaking of packed earnings calls, Bristol Myers definitely delivered on that front. Let's start with the headline numbers because they tell quite a story about this company's transformation.

**ALEX**: Absolutely. So Q4 revenue came in flat year-over-year at about $12.5 billion, but here's the key detail that investors need to understand - their growth portfolio, which includes all their newer drugs, grew 15% in the quarter and represented nearly 60% of total revenue. That's a massive shift from where this company was just a few years ago.

**JORDAN**: Right, and for the full year, that growth portfolio grew 17%. What's really impressive is that despite losing roughly $4 billion in revenue from legacy products - we're talking about patent cliffs and generic competition - the growth portfolio almost completely offset those declines. That's the kind of pipeline execution that pharma investors dream about.

**ALEX**: Let's talk about some of those growth drivers. Reblozyl, their blood disorder treatment, crossed $2 billion in annual sales. Breyanzi, their CAR-T cell therapy, grew 47% in Q4. And then you have Camzyos for heart disease growing 57%. These aren't just incremental gains - these are blockbuster-level products hitting their stride.

**JORDAN**: And here's what caught my attention from CEO Christopher Boerner's comments - he emphasized they're entering 2026 with "good momentum." But the real story is what's coming in the pipeline. They're expecting six registrational data readouts in the second half of 2026. That's potentially six new revenue streams or major label expansions.

**ALEX**: Jordan, let's break down that pipeline because it spans multiple therapeutic areas. You've got Milvexian for atrial fibrillation and stroke prevention - that's a massive market where they're trying to compete with their own Eliquis. Then there's admilparent for lung fibrosis, and several multiple myeloma treatments. This isn't just one bet - it's a diversified portfolio of shots on goal.

**JORDAN**: Speaking of Eliquis, that was probably the most complex part of the call. The drug is actually expected to grow 10-15% in 2026, which surprised me given it's facing patent cliffs. But management explained they took a strategic pricing reduction that eliminates certain penalty rebates while expanding patient access.

**ALEX**: That's a fascinating strategy. CFO David Elkins explained that the roughly 40% price reduction actually helps them competitively because it removes inflationary penalties that had been building up over years. It's counterintuitive - lower prices leading to higher growth - but it makes sense when you understand the complex rebate structures in pharma.

**JORDAN**: However, they're also guiding for a $1.5 to $2 billion step-down in Eliquis revenue from 2026 to 2027, primarily due to European patent expiries. So investors are looking at one good year before facing those headwinds.

**ALEX**: Let's talk about their cost management because this is where Bristol Myers is really showing discipline. They delivered $1 billion in cost savings in 2025 and expect another billion over 2026-2027. But here's the smart part - they're reinvesting some of those savings into growth initiatives like their partnership with BioNTech on pemiglatinib.

**JORDAN**: That partnership caught

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm joined by my co-host Jordan. Today we're diving into Booking Holdings' fourth quarter earnings call - and wow, what a quarter they had.

Before we get started though, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And speaking of wow - Glenn Fogel just celebrated his 26th year at the company! That might make him the longest-tenured executive in tech. But beyond that milestone, Booking absolutely crushed their fourth quarter numbers.

**ALEX**: Let's break down those numbers, Jordan. Room nights hit 285 million - that's a 9% year-over-year increase that actually exceeded the high end of their expectations. And both gross bookings and revenue jumped 16%. What's driving this growth?

**JORDAN**: The strength is really coming from Asia and the U.S., both delivering low double-digit growth. What I found interesting is that the U.S. acceleration has been building all year - they went from low single-digit growth in the first half to low double-digit growth in Q4. That's a pretty impressive turnaround.

**ALEX**: And the profitability story is even better. Adjusted EBITDA reached $2.2 billion, up 19% year-over-year, with margins expanding 80 basis points to nearly 37%. A big driver here is their transformation program that launched in late 2024.

**JORDAN**: Right, and this transformation program is fascinating. They've already achieved $550 million in annual run-rate savings - hitting the high end of their guidance. CFO Ewout Steenbergen said they expect $500 to $550 million in additional in-year savings for 2026. That's serious operational efficiency.

**ALEX**: But here's what I love about their strategy - they're not just pocketing those savings. They're reinvesting about $700 million above baseline into strategic priorities like AI, their connected trip vision, and geographic expansion. It's classic reinvestment for growth.

**JORDAN**: Speaking of AI, Glenn Fogel had some really compelling commentary on this. He talked about how they've been using AI for over a decade, but now with generative AI, they're rolling out what he calls "agentic capabilities" across their platforms. And unlike a lot of companies that talk about AI but don't show results, Booking is actually seeing it in their P&L.

**ALEX**: That's a great point. Steenbergen specifically called out how their customer service costs are actually down year-over-year despite 10% booking growth. That's a roughly 10% decline in customer service cost per booking - real, measurable AI impact.

**JORDAN**: Now let's talk about their competitive moat, because there was a really interesting exchange about large language models potentially disrupting travel booking. An analyst asked about companies like ChatGPT potentially becoming travel agents.

**ALEX**: And Fogel's response was brilliant. He basically said - good luck with that! He pointed out that Booking works with over 4 million properties, processes 100+ payment methods across 50+ currencies, deals with regulations across 200+ countries, and has thousands of partner service people. That's not something you just replicate overnight.

**JORDAN**: Exactly. He compared it to their relationship with Google - Google captures demand at the top of the funnel through search, Booking handles the complex backend of actually completing transactions. Both companies have thrived in that relationship, and he sees a similar dynamic potentially playing out with AI companies.

**ALEX**: Let's touch on their loyalty program, Genius, because the numbers there are impressive. Level 2 and 3 Genius members now represent over 30% of their active base but account for a high

This episode includes AI-generated content.

**Beta Finch Podcast Script: American Express Q4 2025 Earnings**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

**JORDAN**: And I'm Jordan. Today we're diving into American Express's fourth quarter 2025 results, which dropped some pretty impressive numbers this morning.

**ALEX**: Before we jump in, just a quick reminder - this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: So Alex, let's start with the headline numbers because American Express really delivered here.

**ALEX**: Absolutely. They posted record full-year revenues of $72 billion - that's up 10% year-over-year. Earnings per share came in at $15.38, which represents 15% growth excluding some gains. And here's what I found particularly striking - they're guiding for 2026 revenue growth of 9% to 10% with EPS between $17.30 and $17.90.

**JORDAN**: That guidance is solid, but what really caught my attention was their card fee growth. Jordan, they hit a record $10 billion in net card fees for the year, growing at 18%. That's thirty consecutive quarters of double-digit card fee growth. That's the kind of consistency that makes CFOs everywhere jealous.

**ALEX**: And it's not just about the numbers - it's about what's driving them. CEO Stephen Squeri talked extensively about their "investment philosophy," and I think this is key to understanding American Express's strategy. They spent $6.3 billion on marketing in 2025 - that's up 75% since 2019.

**JORDAN**: Right, but here's what's smart about their approach - they're not just throwing money at marketing. They're being incredibly strategic about it. During the quarter, they actually reallocated marketing dollars away from lower-cost cash back products toward their premium Platinum cards. The percentage of fee-paying products in their US consumer portfolio jumped 8 percentage points year-over-year.

**ALEX**: That Platinum card refresh is really the star of the show here. Launched in September, it's already performing better than expectations. Squeri mentioned they're seeing high customer demand, excellent engagement, great credit quality, and no change in retention rates even as the new fees kick in.

**JORDAN**: The engagement numbers are pretty remarkable. They launched a new Platinum travel app, and travel bookings were up 30% in the fourth quarter. Restaurant spending through their Resy platform was up 20%. When you can get customers to spend more while maintaining pristine credit quality, that's the holy grail of credit card business.

**ALEX**: Speaking of credit quality, let's talk about that because it's been a competitive advantage for American Express. Their delinquency and write-off rates remained flat throughout the year and are still below 2019 levels. CFO Christophe Le Caillec noted they expect credit metrics to remain "generally stable" in 2026.

**JORDAN**: That's in stark contrast to many competitors who are guiding for increases in credit losses. It really speaks to the quality of American Express's customer base. They're targeting that premium segment - millennials and Gen Z customers are now the largest share of US consumer spending, with average ages of 33 on Platinum and 29 on Gold cards.

**ALEX**: Now, one number that had investors asking questions was net card acquisitions, which were down a bit. But I think Squeri's response was telling - he said they don't focus on acquiring cards, they focus on acquiring revenue. And they're hitting their revenue targets.

**JORDAN**: Exactly. It's about quality over quantity. They're deliberately shifting toward fee-paying customers, and that's showing up in the economics. The variable customer engagement costs - basically rewards and benefits - stepped up to 45% of revenue in Q4 as they invested in those Pla

This episode includes AI-generated content.

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into AppLovin's absolutely explosive Q4 2024 results. Before we get started though, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And wow, where do we even start with these numbers? AppLovin just delivered what CEO Adam Foroughi called "the most exceptional year we have ever delivered." We're talking about Q4 revenue of $1.66 billion, up 66% year-over-year, with adjusted EBITDA of $1.4 billion at an 84% margin. That's not a typo, folks - 84% margins.

**ALEX**: Those margins are just insane, Jordan. To put this in perspective, AppLovin is basically printing money at this scale. For the full year, they hit $5.48 billion in revenue, up 70% year-over-year, with $4.51 billion in adjusted EBITDA. That's nearly $4 billion in free cash flow for the year. And here's the kicker - they guided Q1 to sequential growth of 5% to 7%, which is unusual since Q1 is typically softer than Q4.

**JORDAN**: Right, and that sequential growth guidance is particularly impressive because it's happening despite typical seasonality headwinds AND the fact that their e-commerce business, which is still ramping, actually has worse Q1 seasonality than gaming. So the underlying strength in their core gaming business and the momentum in e-commerce must be really significant.

**ALEX**: Let's talk about the elephant in the room though - all this AI and competition fear that's been weighing on the stock. Adam Foroughi came out swinging on this topic right from the opening remarks. He basically said there's a "real disconnect between market sentiment and the reality of our business."

**JORDAN**: Yeah, his argument was fascinating. He essentially said that competition actually helps them because of how their MAX auction works. When competitors win impressions, it's usually the lower-value ones that AppLovin's model wasn't that confident about anyway. Meanwhile, AppLovin gets to collect a 5% take rate from the winning bidder. So more competition can actually expand the pie rather than just redistributing it.

**ALEX**: And on the AI disruption front, Foroughi made a counterintuitive argument. He said that if AI makes games easier to create, that actually benefits AppLovin because it creates more content, and when content becomes abundant, discovery becomes scarce. That's exactly what AppLovin's platform is designed for - efficiently matching the right user to the right content.

**JORDAN**: The e-commerce expansion is really the big growth story here though. They launched self-service onboarding in Q4 on a referral-only basis, and they're seeing some incredible early metrics. Adam mentioned they're seeing roughly 30-day LTV to customer acquisition cost breakeven when they test marketing the platform, which is exceptional for a lead generation model.

**ALEX**: That's a remarkable metric, especially when you consider they're converting 57% of qualified leads to live advertisers. Adam said they want to get that conversion rate closer to 100% before going to general availability, which they still expect in the first half of 2025. And they shared this amazing case study of an Israeli cookware company that grew from $4 million to $16 million in revenue last year, with 65% of their user acquisition spend on AppLovin's platform.

**JORDAN**: The creative automation piece is really interesting too. AppLovin is piloting generative AI tools with over 100 customers to help create ad components automatically. Right now, top gaming companies run tens of thousands of ads simultaneously, while top e-commerce companies are only running hundreds. If they can bridge that gap with AI-generated creative tools,

This episode includes AI-generated content.

**Beta Finch Podcast Script**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into some fascinating quarterly results. Jordan, we've got Amphenol's Q4 2025 earnings to discuss today - and wow, what a quarter this was.

JORDAN: Absolutely, Alex. But before we get into these impressive numbers, I need to share our standard disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Thanks Jordan. Now, let's talk Amphenol - because these results are genuinely remarkable. We're looking at a company that just posted record sales of $6.4 billion for the quarter, up 49% in US dollars and 37% organically. For the full year, they hit $23.1 billion in sales. Jordan, they've literally more than doubled their revenue in just four years.

JORDAN: That's incredible scale, Alex. And what really caught my attention was their book-to-bill ratio - 1.31 to one in Q4, driven by a record $8.4 billion in orders. That's 68% growth in orders compared to last year. CEO Adam Norwitt was pretty clear about what's driving this: AI infrastructure investments are creating unprecedented demand for their interconnect products.

ALEX: Right, and this isn't just a revenue story. Their adjusted operating margin hit 27.5% in the quarter - that's a 510 basis point improvement year-over-year. For a company growing this fast, those margin numbers are exceptional. Jordan, what did you make of their strategy around acquisitions?

JORDAN: This is where it gets really interesting, Alex. They just closed their largest-ever acquisition - the CommScope CCS business - for what became over $4 billion in annualized sales after strong momentum. Norwitt was fascinating when he talked about this deal. He said they don't use the words "integration" or "synergy" at Amphenol. Instead, they let acquired companies evolve into the Amphenol family while maintaining their entrepreneurial culture.

ALEX: That's such a unique approach. And strategically, this CommScope acquisition is huge for them. It dramatically expands their fiber optic capabilities, which complements their traditional strength in high-speed copper interconnects. As Norwitt put it in the call, they can now offer customers solutions across "the entirety of the interconnect spectrum."

JORDAN: Exactly. And the timing couldn't be better with AI driving demand for both copper and fiber solutions. Speaking of AI, let's break down their IT datacom segment - it represented 38% of sales in Q4 and grew 110% organically. That's not a typo, folks - one hundred and ten percent growth.

ALEX: The breadth of their AI business really stood out to me, Jordan. Norwitt emphasized they don't have any 10% customers, meaning they're diversified across the entire AI stack - from hyperscalers to equipment manufacturers to chip designers. That's a much safer position than being dependent on one or two major customers.

JORDAN: And those record orders we mentioned? They're giving customers extended order windows to help share investment risk for these complex, high-tech products. Customers are essentially making solid commitments that give Amphenol confidence to make the capital investments needed for these next-generation systems.

ALEX: Let's talk about what this means geographically. One surprise was their strength in Europe, where they saw robust organic growth in both automotive and industrial markets. CFO Craig Lampo noted their strongest automotive growth in Q4 was actually in Europe - quite different from the doom and gloom we usually hear about that region.

JORDAN: That's a great point. And looking ahead, their Q1 2026 guidance is impressive: $6.9 to $7 billion in sales and $0.91 to $0.93 in adjusted EPS. That represents 43-45% sales growth and 44-48%

This episode includes AI-generated content.

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into AMD's Q2 2025 earnings call. Now, before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Thanks Alex. And wow, what a quarter for AMD! They absolutely crushed it with record revenue of $7.7 billion - that's up 32% year-over-year and beat the midpoint of their guidance. But there's definitely a story of two halves here.

ALEX: Exactly right, Jordan. On one hand, you've got this incredible momentum in traditional semiconductors - record sales for both their EPYC server chips and Ryzen consumer processors. But then there's this big cloud hanging over their AI GPU business with those U.S. export controls to China. Let's break down the numbers first.

JORDAN: So the headline numbers look strong, but dig a little deeper and you see some complexity. They reported earnings per share of 48 cents, down from 69 cents last year. But here's the kicker - they took an $800 million inventory write-down related to those export restrictions on AI chips to China. Without that charge, gross margins would have been 54% instead of the reported 43%.

ALEX: That write-down is massive, Jordan. It's essentially AMD saying "we built all these high-end AI chips for China, but now we can't sell them." CEO Lisa Su mentioned that most of this wasn't finished goods sitting on shelves - it was work-in-process inventory that will take a couple quarters to work through if and when licenses get approved.

JORDAN: Right, and that's actually somewhat encouraging because it means they're not stuck with warehouses full of obsolete products. Speaking of AI chips, let's talk about what's working. Their new MI350 series started shipping in June - ahead of schedule - and Su sounded genuinely excited about customer adoption.

ALEX: The MI350 story is fascinating. Su mentioned they're seeing faster adoption than expected, with customers wanting to deploy at scale rather than the smaller pilot deployments they saw with the MI300 series. They're positioning the MI355 as competitive with NVIDIA's B200 and GB200 chips, claiming 40% more tokens per dollar for inference workloads.

JORDAN: And here's where it gets really interesting - they announced this massive collaboration with Saudi Arabia through something called HUMAIN, described as a "multibillion-dollar" AI infrastructure deal. Plus they mentioned over 40 active sovereign AI engagements globally. This could be a game-changer for AMD's positioning against NVIDIA.

ALEX: Absolutely. But let's not forget their bread and butter businesses, because those are absolutely on fire right now. Client and Gaming revenue jumped 69% year-over-year to $3.6 billion. That's driven by what Su called "record desktop CPU sales" with their Ryzen processors consistently topping bestseller lists.

JORDAN: The client story is particularly impressive because it's not just about volume - they're moving up-market. Revenue growth of 67% year-over-year in client CPUs is largely coming from higher average selling prices as they capture more premium segments. And they're finally making real inroads in enterprise PCs, which has been a tough nut to crack against Intel.

ALEX: Data center CPUs are another bright spot. Despite all the focus on AI GPUs, AMD set records for both cloud and enterprise CPU sales. Su mentioned they've now had 33 consecutive quarters of server market share gains. Think about that - that's over eight years of steady progress against Intel.

JORDAN: The guidance for Q3 is pretty telling too. They're calling for revenue of about $8.7 billion, which implies 28% year-over-year growth. The key driver is supposed to be that MI350 ramp we talked about, even withou

This episode includes AI-generated content.

# Beta Finch Podcast Script - Analog Devices Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you the most important takeaways from quarterly reports. I'm Alex.

**JORDAN:** And I'm Jordan. Before we dive into today's earnings, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX:** Thanks Jordan. Today we're breaking down Analog Devices' first quarter 2026 results, and wow - what a quarter this was. ADI absolutely crushed it across the board, with revenue hitting $3.16 billion, up 30% year-over-year and coming in at the high end of guidance.

**JORDAN:** That's right, Alex. And it wasn't just a revenue beat - earnings per share came in at $2.46, up 51% year-over-year, while operating margins expanded to 45.5%. But what really caught my attention was their guidance for Q2. They're projecting $3.5 billion in revenue, which would be about 11% sequential growth - way above their typical 4-5% seasonality.

**ALEX:** Absolutely massive guide. Now Jordan, let's talk about what's driving this performance because CEO Vincent Roche spent a lot of time on the call talking about their AI exposure. They mentioned that their automated test equipment and data center businesses now make up close to 20% of total revenue - that's over $2 billion on a run-rate basis.

**JORDAN:** That's a huge number, and here's the breakdown: about 40% of that AI-related revenue is from automated test equipment, or ATE, which grew about 40% last year and accelerated further in Q1. The remaining 60% is data center, split roughly equally between power management and optical connectivity solutions. Both segments are seeing what Roche called "substantial returns" from their AI investments.

**ALEX:** What I found fascinating was Roche's deep dive into their data center power story. He broke it down into two categories - power delivery, which he called "the vascular system," and power control, which he described as "the brain of the data center energy system." ADI's positioning themselves as essential to managing the massive power requirements of AI infrastructure.

**JORDAN:** Right, and this isn't just theoretical. CFO Richard Puccio mentioned that their data center business grew approximately 50% in fiscal 2025 and saw accelerated growth in the most recent quarter. When you combine that with the ATE growth, you're looking at some serious momentum in their highest-margin businesses.

**ALEX:** Now let's talk about the segment performance because it was pretty broad-based. Industrial, their largest segment at 47% of revenue, was up 38% year-over-year with all subsegments growing at least 25%. That includes record quarters for both ATE and aerospace & defense.

**JORDAN:** Communications was another standout, up 63% year-over-year, driven by that AI data center demand we mentioned plus a cyclical recovery in wireless. Even automotive, which has been a bit soft, still managed 8% year-over-year growth despite some tariff-related headwinds.

**ALEX:** Speaking of automotive, that was one of the more interesting parts of the Q&A. Management acknowledged they're seeing some sequential weakness there, calling it "flat to down" for Q2, largely due to what they called a "tariff and macro pull-in unwind." But they're confident about the second half of the year.

**JORDAN:** Yeah, and CFO Puccio was pretty clear that nothing's changed with their strong market position in automotive. They've been gaining significant content and share, particularly in Level 2+ ADAS systems, and they expect automotive to grow for the full fiscal year despite the first-half headwinds.

**ALEX:** Now Jordan, let's talk margins because this is where ADI really shines. Gross m

This episode includes AI-generated content.

**Beta Finch Podcast Script: AbbVie Q4 2025 Earnings**

---

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we digest the latest corporate earnings so you don't have to. I'm Alex.

JORDAN: And I'm Jordan. Today we're diving into AbbVie's fourth quarter 2025 results, and wow, what a story this pharmaceutical giant has to tell.

ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Absolutely. Now Alex, AbbVie just delivered what CEO Robert Michael called "another excellent year," and the numbers certainly back that up. Let's start with the headline figures.

ALEX: The numbers are pretty impressive, Jordan. AbbVie hit $61.2 billion in adjusted net revenues for the full year - that's a record high and beat their initial guidance by over $2 billion. They're looking at 8.6% sales growth despite facing nearly $16 billion in HUMIRA erosion since it lost exclusivity.

JORDAN: That HUMIRA erosion is the elephant in the room, isn't it? But what's fascinating is how they've more than offset those losses. Their adjusted earnings per share came in at $10 - that's 54 cents above their initial guidance midpoint. It really shows the power of their newer drugs.

ALEX: Exactly, and speaking of those newer drugs, let's talk about the real stars of the show - SKYRIZI and RINVOQ. These two immunology powerhouses are absolutely crushing it.

JORDAN: The numbers are staggering. Combined, SKYRIZI and RINVOQ delivered about $25.9 billion in revenue - that's an $8 billion increase year-over-year. SKYRIZI alone hit $5 billion in the quarter with 31.9% operational growth, while RINVOQ came in at nearly $2.4 billion with 28.6% growth.

ALEX: And here's what caught my attention - they're already exceeding their 2027 long-term guidance by half a billion dollars. For 2026, they're projecting combined sales of over $31 billion for these two drugs. That's remarkable momentum.

JORDAN: What's really interesting is how they're dominating in specific markets. In psoriasis, SKYRIZI has over 45% prescription share in the U.S. biologic market, and their capture rates for new patients are exceeding 55% - that's four times higher than their next closest competitor.

ALEX: The competitive dynamics in IBD are particularly noteworthy. Despite new competition, SKYRIZI maintains a 75% capture rate in frontline IBD treatment, and it's even higher - 80% - specifically in Crohn's disease.

JORDAN: Now let's talk about what's really exciting for the future - their neuroscience portfolio. This segment delivered over $10.7 billion in revenue with nearly $1.8 billion in growth. But the real story here is Vialev, their Parkinson's treatment.

ALEX: Vialev hit $183 million in the quarter - up 33% sequentially - and management is now projecting it'll reach blockbuster status in 2026. That's a billion-dollar drug in its early launch phase. Pretty remarkable.

JORDAN: And they're not stopping there. They see their entire Parkinson's franchise, including Vialev, Duopa, and the upcoming Tavapadon, potentially reaching $5 billion in peak sales. Add their migraine franchise, which they also expect to exceed $5 billion, and you're talking about some serious long-term growth drivers.

ALEX: Let's shift to their pipeline because that's where AbbVie is really investing for the future. They spent nearly $1 billion more on R&D in 2025, fully funding 90 clinical programs. They also invested over $5 billion in business development.

JORDAN: Some of those acquisitions are fascinating - they picked up an in-vivo CAR-T platform, next-generation psychedelics for depression, a long-acting amylin analog for obesity, and even a novel siRNA platform. They're clearly positioning for the next decade of growth.

ALEX: Speaking of p

This episode includes AI-generated content.